Analysis of Pump Thrombosis in the Intermacs Database
|
|
- Magdalene Adams
- 5 years ago
- Views:
Transcription
1 Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania Health System 1
2 Disclosures Consultant for Thoratec and Heartware 2
3 Perceived increase in incidence of HMII pump thrombosis after 2011 by several large VAD centers compared to HMII pivotal trial FDA/NHLBI request Intermacs to investigate 3
4 Figure 1 Overall Survival % Survival Months post implant % Survival 1 95% 3 91% 6 87% 12 80% 24 69% 36 58% 48 46% n=6910, deaths=1772 Event: Death with a device in place (censored at transplant and recovery) Months post implant 4
5 Figure 2 No change in survival by Implant year p(overall) =.63 % Survival Implant Year n Deaths (with a device in place) Totals Event: Death with a device in place (censored at transplant and recovery) Months post implant 5
6 Figure 3 % Freedom from Device Exchange p(overall) <.0001 Implant Year n Events Totals Increase in pump exchange per year Event: Device Exchange (censored at death, transplant and recovery) Months post implant 6
7 Table 1 Device Removal Events n Removed (exchanged) due to a problem 561 Thrombus 288 Elective 94 Emergent 177 Unknown 17 Probable Thrombus 49 Elective 25 Emergent 21 Unknown 3 Infection (Not thrombus) 76 Elective 38 Emergent 11 Unknown 27 Not Thrombus/Unknown Infection 120 Elective 52 Emergent 68 Not Thrombus/Not Infection 28 Unknown 28 Main Event Exchanges or deaths due to thrombus n=382 Device removed due to recovery 133 Death: Device not functionally normally 98 Thrombus 27 Probable Thrombus 18 Not Thrombus 53 Totals 792 7
8 Figure 5 % Freedom from Device Exchange or death due to thrombus % Freedom at Implant Year n Events 6 mos 12 mos 36 mos % 98% 92% % 99% 95% % 97% 90% % 94% % 93% ---- Totals Event: Device Exchange or death due to thrombus* (censored at death, transplant and recovery) Increase in pump exchange/death due to thrombus or death from 1% to 6% p(overall) <.0001 Months post implant *Thrombus events include probable thrombus events 8
9 Table 2 Pump Exchanges due to Thrombus: n=337 Exchange Era Elective Emergent Total (24.3%) 28 (75.7%) 37 (100.0%) * 110 (39.3%) 170 (60.7%) 280 (100.0%) Overall p value =.08 * 2013 includes exchanges from 01/01/2013 through 06/30/2013
10 Figure 4 % Freedom from exchange or death due to thrombus Months % Freedom 6 97% 12 95% 24 92% 48 86% n=6910, events=382 Event: Device exchange or death due to thrombus Hazard Events/Month Months post Implant 10
11 Figure 6 % Freedom from Device Exchange or death due to thrombus % Freedom by implant year p(overall) <.0001 Event: Device Exchange or death due to thrombus* (censored at death, transplant and recovery) Hazard by implant year Events/Month Months post implant *Thrombus events include probable thrombus events 11
12 Occurrence and Incidence of Confirmed Pump Thrombosis Stratified According to Implantation Date. Starling RC et al. N Engl J Med 2014;370:33-40
13 Table 4 Risk Factors for Device Exchange or Death due to Thrombus (Time Zero = 1 Month Post Implant) Risk Factor hazard ratio p-value Implant year (later) 1.46 <.0001 Age (younger) <.0001 White race BMI (larger) LVEF above 20% LDH at 1 month (higher) < Hazard ratio denotes the increased risk for a 60 year compared to a 70 year old patient 2 Hazard ratio denotes the increased risk for a 10 unit increase in BMI 3 Hazard ratio denotes the increased risk for an increase in LDH from 500 to 1000 units BMI, body mass index; LVEF, left ventricular ejection fraction; LDH, lactate dehydrogenase
14 Figure 13 By LDH Groups % Freedom from Device Exchange or Death due to Thrombus LDH group n Events Missing > Totals Event: Device Exchange due to Thrombus** (censored at death, transplant and recovery) p(overall) <.0001 ** Thrombus events include probable thrombus LDH, lactate dehydrogenase Months post implant 14
15 Figure 8 1 st device, n=6910, deaths=1604 % Survival Exchange due to Thrombus n=337, deaths=80 Exchange due to Infection/Other n=224, deaths=66 p(overall) <.0001 Event: Death with a device in place (censored at transplant and recovery) Months post implant 15
16 Table 3 Primary Cause of Death within 3 months After Pump Exchange or After Primary Implant* death due to Thrombus Primary Cause of Death n % n % Circulatory Failure % % Multisystem Organ Failure % % CNS Event % % Infection % 1 6.7% Respiratory Failure % 1 6.7% Device Malfunction % 0 0.0% * Censored at devices exchange CNS, central nervous system
17 Figure 9 % Freedom from Infection n=6910, events=3206 n=337, events=131 p =.008 Event: Time to first Infection Months post Implant 17
18 Figure 10 n=6910, events=619 % Freedom from CVA n=337, events=37 p <.0001 Event: Time to first CVA Months post Implant CVA, cerebrovascular accident 18
19 Figure Median Visual Analog Scale (VAS) Main Event n=337: Exchanges due to Thrombus Median 1st Operation (prior to exchange) 2 nd Operation (exchanges due to thrombus) p value st Operation (n) nd Operation (n)
20 Figure 14 3 Median INR 1month post implant forward INR st operation Q1-25% Q3-75% INR, International normalized ratio Post Implant Follow-up by Quarter/Year 20
21 Limitations Pump Design/Production Intermacs can not give granular data on subtle differences/changes in clinical practice/patient selection overtime that may affect outcome Implantation techniques ie inflow angles Intensity of anticoagulation; compulsive f/u heparin bridging; Pump speed vs AV opening BP management 22
22 Changes Over Time GI bleeding decrease in anticoagulation goals Elimination of heparin bridging Decrease rpms to allow AV opening Pump Design/Production 2011 changes in outflow graft ; bend relief software changes 2011 Marked ramp up in production 23
23 Summary 6 fold Increase in Pump Exchange or death due to thrombosis in 2011 to 6% from 1% in 2009 Early Hazard of Pump thrombosis in first 3 months after 2011 not seen prior to 2011 Overall survival not changed (I yr 80%) BUT if you have a pump exchanged for thrombosis your survival is decrease (1 yr 70%) and your chance of stroke or infection is increased 24
24 Summary Risk factors for early Pump thrombosis is predominantly Pt year (2011) and early LDH rise after implant; other risk factors younger age; white; large BMI; LVEF > 20% 25
25 Conclusions (personal not intermacs) Most important change post 2011 is not increase rate of thrombosis but new early hazard of thrombosis< 3 months; different than late thrombosis Whatever is happening is happening in the OR or early postop Importance of HMII inflow cannulae ventricular alignment; bridging heparin Early LDH rise not seen prior to 2011 causative or result of early thrombus? Great variations of incidence of thrombosis between sites ( 1% to >20%) Detailed statistical review of different site practices (consortium of high and low incident sites) is needed to determine subtle difference in operative/implantation and pt care practices that may elucidate important risk factors for thrombosis Will allow hypothesis generation to validate in prospective study (PREVENT) Therapeutic window for HMII is more narrow now than prior to 2011 Multifactorial etiology- pump; implantation; pump management (anticoagulation, speed); patient; patient care?anticoagulation goals in high thrombosis incident sites higher now than prior to 2011 Importance of pump flow pass the bearing to dissipate heat rpms > 9000 if possible Continued Thoratec review of manufacturing practices and changes 26 made in pump in 2011
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationDiagnosis of Device Thrombosis
Diagnosis of Device Thrombosis Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's Medical Center / Texas Heart Institute Trends in
More informationHow do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS
How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS Rey P. Vivo, MD 1 ; Selim R. Krim, MD 2 ; Jerry D. Estep, MD 3 ; Wissam
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationComplications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationRegional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry
Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry Selim Krim, MD 1 ; Rey Vivo, MD 2 ; Patrick Campbell, MD 1 ; Jerry Estep, MD 3
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationEcho in Heart Failure
Echo in Heart Failure Karima Addetia, MD Heart Failure: Definition A clinical syndrome that results from impairment of ventricular filling or ejection of blood. Manifestations include dyspnea and fatigue,
More informationSafety Evaluation of the Pericardial HeartWare MVAD System
Safety Evaluation of the Pericardial HeartWare MVAD System Edwin C. McGee, Jr. M.D. Surgical Director, Heart Failure, Heart Transplantation, and Mechanical Assistance Bluhm Cardiovascular Institute, Northwestern
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationPump thrombosis A riddle wrapped in a mystery inside an enigma
Keynote Lecture Series Pump thrombosis A riddle wrapped in a mystery inside an enigma Arie Blitz Division of Cardiac Surgery, University of Cincinnati Medical Center, Cincinnati, OH, USA Correspondence
More informationThe Balancing Act Bleeding and Thrombosis in MCS. Muhammad Adil Soofi
The Balancing Act Bleeding and Thrombosis in MCS Muhammad Adil Soofi Road Map Survival and complications with LVAD What is the Burden of thrombosis and bleeding Why Bleeding and Thrombosis happen When
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationAdverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:
Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 17 Adverse Event Infection Was there a major infection? Date of
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More informationSize Limitation for Current Continuous Flow Pumps: How young can we go?
Size Limitation for Current Continuous Flow Pumps: How young can we go? Iki Adachi, M.D. Associate Surgeon Texas Children s Hospital Assistant Professor Baylor College of Medicine How young can we go?
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationUnexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis
The new england journal of medicine Original Article Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis Randall C. Starling, M.D., M.P.H., Nader Moazami, M.D., Scott C. Silvestry,
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationStrengthening Your VAD Program
Disclosure: I have no financial conflicts of interest. Strengthening Your VAD Program Octavio E. Pajaro MD, PhD Chair, Cardiothoracic Surgery Mayo Clinic Arizona Surgical Director, Heart Transplantation
More informationAdverse Event - Intermacs
version date: 6/28/2017 Adverse Event - Intermacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 24 version date: 6/28/2017
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationQUICK REFERENCE HEARTWARE HVAD PUMP FLOW INDEX
QUICK REFERENCE HEARTWARE HVAD PUMP FLOW INDEX LOW PULSATILITY, LOW FLOW HVAD waveforms do NOT conform to a single, classic appearance, and are not intended for diagnostic purposes. Waveforms represent
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationHeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial
http://www.jhltonline.org FEATURED ARTICLES HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial Mark S. Slaughter,
More informationLeft Ventricular Assist Devices LVAD. North Country EMS Program Agency 3/21/12
Left Ventricular Assist Devices LVAD North Country EMS Program Agency 3/21/12 Objectives Describe indications for and functions of ventricular assist devices (LVAD) Differentiate assessment findings of
More informationUNIVERSITY OF UTAH HEALTH CARE HOSPITALS AND CLINICS
UNIVERSITY OF UTAH HEALTH CARE HOSPITALS AND CLINICS CARDIAC MECHANICAL SUPPORT PROGRAM GUIDELINES CARDIAC MECHANICAL SUPPORT: LVAD BASICS FREQUENT SCENARIOS AND TROUBLESHOOTING Review Date: July 2011
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationBerlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System
Berlin Heart Pediatric Assistance Device: The Beginnings, The Teachings And The Cruising Speed : A Monocentric Experience With The Same System Roland Henaine, Mathieu Vergnat, Geoffray Keller, Magali Veyrier,
More informationJapanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage Japanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist
More informationEnd-Stage Heart Failure Care: Advances in Technology and Patient Survival
End-Stage Heart Failure Care: Advances in Technology and Patient Survival Colleen Ciampa, RN, MN, CNS, NP-C St. Vincent Hospital Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Program
More informationJapanese Multicenter Outcomes With the HeartMate II Left Ventricular Assist Device in Patients With Small Body Surface Area
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Surgery Japanese Multicenter Outcomes With the HeartMate II Left Ventricular
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationChallenges to MCS Use in the Middle East
Challenges to MCS Use in the Middle East Feras Khaliel, MD, Ph.D Consultant Cardiac Surgeon Associate Professor of Surgery, Alfaisal Univerisity King Faisal Specialist Hospital & Research Center Dr. Michael
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationLeft ventricular assist device exchange for the treatment of HeartMate II pump thrombosis
Original Article Left ventricular assist device exchange for the treatment of HeartMate II pump thrombosis Jasmin S. Hanke, Günes Dogan, Leonard Wert, Marcel Ricklefs, Jan Heimeshoff, Anamika Chatterjee,
More informationWhat s New in MCS. and Transplantation. June Transplantation. Reviews:
What s New in MCS June 2016 Kim Anderson, MD, FRCPC Advanced Heart Failure, Mechanical Circulatory Support and Transplantation Toronto General Hospital Kim.anderson@mail.utoronto.ca Farooq Sheikh, MD,
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationAUTOLOGS TM ATLAS ON DEMAND DATA WITH EVERY PATIENT VISIT
AUTOLOGS TM ATLAS ON DEMAND DATA WITH EVERY PATIENT VISIT Introduction The Autologs Atlas will guide your introduction to our new Autologs service and the information recorded by the HeartWare HVAD TM
More informationAdverse Event. Adverse Event Status. version date: 12/10/ of 21. Please enter the date of the event you are reporting:
version date: 12/10/2015 Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 21 version date: 12/10/2015 Adverse Event
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationFEATURE. 58 EMERGENCY MEDICINE I FEBRUARY
FEATURE 58 EMERGENCY MEDICINE I FEBRUARY 2016 www.emed-journal.com Troubleshooting the Left Ventricular Assist Device Alicia S. Devine, JD, MD In an update and complement to a previously published article,
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationEvaluation and treatment of pump thrombosis and hemolysis
Featured Article Evaluation and treatment of pump thrombosis and hemolysis Vakhtang Tchantchaleishvili 1, Fabio Sagebin 1, Ronald E. Ross 1, William Hallinan 2, Karl Q. Schwarz 2, H. Todd Massey 1 1 Division
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationWhy Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care
More information1/21/2016. HeartMate II Indications for Use. Ventricular Assist Device Overview. Jon G. Echterling MSN, CCRN, FNP-BC. Learning Objectives
Ventricular Assist Device Overview Jon G. Echterling MSN, CCRN, FNP-BC February 5, 2016 Learning Objectives Identify the components and operation of the HeartMate II LVAD Describe the path blood follows
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationRay Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
More informationHeart Transplantation
Heart Transplantation Age and Outcome Mayo Clinic Richard Daly, MD Professor of Surgery Surgical Director Heart & Lung Transplantation 2014 MFMER 3346076-1 Rochester, Minnesota 2014 MFMER 3346076-2 The
More informationAdverse Event Not Started
Adverse Event t Started Adverse Event Status Print this Form t Started Please enter the date of the event you are reporting: Please enter a label describing this event: 2014 InterMACS [InterMACS_New] 1
More informationIntrapericardial Left Ventricular Assist Device for Advanced Heart Failure
The new england journal of medicine Original Article Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure Joseph G. Rogers, M.D., Francis D. Pagani, M.D., Ph.D., Antone J. Tatooles,
More informationArtificial Heart Program
Artificial Heart Program Provider Review: General VAD Overview Indications for VAD Bridge to transplant (BTT) historically most common (~80%) allow rehab from severe CHF while awaiting donor Bridge to
More informationEchocardiographic Structural Assessment Pre- LVAD
None Disclosures Echocardiographic Structural Assessment Pre- LVAD LVEF ( 25% for DT LVAD) Right ventricle Valvular disease Intra- cardiac shunts Intra- cardiac thrombi Ascending aorta Case 1 50 yo M
More informationReadmissions: an unavoidable nemesis
Readmissions: an unavoidable nemesis This presentation was presented at the Thoratec Corporation Economic Summit held on September 30-October 2 in La Jolla, CA. Please note that this presentation and content
More informationNone. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
More informationHow to Develop a Comprehensive Ventricular Assist Device Program
How to Develop a Comprehensive Ventricular Assist Device Program Rodrigo V. González, MD, MS Sección de Cirugía Cardiovascular División de Cirugía Facultad de Medicina Pontificia Universidad Católica de
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationAdverse Event - Pedimacs
version date: 12/19/2017 Adverse Event - Pedimacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 22 version date: 12/19/2017
More informationLeft Ventricular Assist Device: What Should I Report?
2017 SOTA, Tucson, AZ February 21, 2017 11:15 11:40 AM 25 min Left Ventricular Assist Device: What Should I Report? Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate Professor
More informationPROVEN. TRUSTED. COMMITTED. HeartWare HVAD System
PROVEN. TRUSTED. COMMITTED. HeartWare HVAD System PROVEN. TRUSTED. COMMITTED. 42% of all heart transplant patients worldwide are bridge to transplant with a VAD. 1 Our commitment to advance the treatment
More informationMechanical Circulatory Support for Unstable Heart Failure
Mechanical Circulatory Support for Unstable Heart Failure Michael A. Acker, MD William Measey Professor of Surgery Chief of Cardiovascular Surgery University of Pennsylvania Health System O.H. Frazier,
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan
ECMO as a bridge to durable LVAD therapy Jonathan Haft, MD Department of Cardiac Surgery University of Michigan Systolic Heart Failure Prevalence 4.8 million U.S. 287,000 deaths per year $39 billion spent
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationFacts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.
10/21/18 1 Facts 5.8 million adults in the US have heart failure. About ½ of those who have HF have a 5 year life expectancy. STRONG Risk Factors for HF* Coronary Heart Disease/MI/Afib COPD Renal Failure
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More informationVeno-Venous ECMO Support. Chris Cropsey, MD Sept. 21, 2015
Veno-Venous ECMO Support Chris Cropsey, MD Sept. 21, 2015 Objectives List indications and contraindications for ECMO Describe hemodynamics and oxygenation on ECMO Discuss evidence for ECMO outcomes Identify
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationCase - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationLeft Ventricular Assist Device as Destination Therapy
Review Left Ventricular Assist Device as Destination Therapy Maya Guglin 1 * and Leslie W. Miller 1 Gill Heart Institute, University of Kentucky, Lexington, KY 1 ORCID: 0000-0001-5746-3135 * Corresponding
More informationFrom Recovery to Transplant: One Patient's Journey
From Recovery to Transplant: One Patient's Journey Tonya Elliott, RN, MSN Assist Device and Thoracic Transplant Coordinator Inova Transplant Center at Inova Fairfax Hospital Falls Church, VA Introduction
More information